Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

13.86 -0.14 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Analyzing ChemoCentryx's Unusual Options Activity ↗
Shares of ChemoCentryx (NASDAQ:CCXI) saw some unusual opt... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Analyst Ratings For ChemoCentryx ↗
Analysts have provided the following ratings for ChemoCentryx (NASDAQ: 
Via Benzinga
News headline image
Why This ChemoCentryx Analyst Is Bullish ↗
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: 
Via Benzinga
News headline image
51 Biggest Movers From Yesterday ↗
Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2... 
Via Benzinga
News headline image
ChemoCentryx Stock Needs To Hold At Support Or It May Slide Lower ↗
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower Thursday, although there looks to be no company-evident news to explain the jump in share price. The stock was... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock increased by 21.06% to $1.31 during Thursday's regular session. The current volume of 70.4 million shares is 943.37% of Progenity... 
Via Benzinga
News headline image
36 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 55% to $13.00. Paltalk engaged ClearThink to lead expanded investor relations program. Farmmi, Inc. (NASDAQ: FAMI) jumped 45.5... 
Via Benzinga
News headline image
Why Are ChemoCentryx's Shares Trading Higher Today? ↗
ChemoCentryx Inc's (NASDAQ: CCXI) partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare... 
Via Benzinga
News headline image
22 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company’s shares jumped around 65% over the previous month. vTv Therapeutics Inc... 
Via Benzinga
News headline image
2 Growth Stocks That Could Take Off Before the End of the Year ↗
They've been struggling thus far in 2021, but things could turn around quickly for these companies. 
Via The Motley Fool
News headline image
NASDAQ:CCXI Long Term Shareholder Notice: Investigation over Potential Wrongdoing at ChemoCentryx, Inc. ↗
San Diego, CA -- (SBWIRE) -- 09/15/2021 -- Certain directors of ChemoCentryx, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
News headline image
ChemoCentryx's Return On Capital Employed Overview ↗
Benzinga Pro data, ChemoCentryx (NASDAQ:CCXI) reported Q2 sales of $1.81 million. Earnings fell to a loss of $38.74 million, resulting in a 32.09% decrease from last quarter. In... 
Via Benzinga
News headline image
ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript ↗
CCXI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
ChemoCentryx: Q2 Earnings Insights ↗
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
News headline image
10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Analyzing ChemoCentryx's Unusual Options Activity ↗
ChemoCentryx (NASDAQ:CCXI) shares experienced unusual options activity on Thursday. The stock price moved down to $15.19 following the option alert. Sentiment: BULLISH Option... 
Via Benzinga
News headline image
2 Beaten-Down Biotech Stocks That Could Bounce Back ↗
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
News headline image
Is Now the Time to Buy ChemoCentryx Stock? ↗
Analysts following this risky biotech stock have changed their tune. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2021 ↗
Upgrades According to Raymond James, the prior rating for Sunnova Energy International Inc (N... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Keybanc cut Alibaba Group Holding Limited (NYSE: BABA) price target from $275 to $270. Alibaba shares rose 0.5% to $212.60 in pre-market trading. Needham boosted SMART Global... 
Via Benzinga
News headline image
ChemoCentryx Stock Is Approaching A Key Level ↗
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-... 
Via Benzinga
News headline image
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7 ↗
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat... 
Via Benzinga
News headline image
Biotech Losers In 2021 That Could Bounce Big In The Second Half ↗
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. Here's a list of biotech stocks that were among the worst performers in the first half but have the potential to... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.